About: Brief Report: Anti‐phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID‐19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Brief Report: Anti‐phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID‐19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Brief Report: Anti‐phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID‐19)
Creator	Zhang, Yan Zhao, Jing Chen, Yu Chen, Huan Zhu, Huadong Zhou, Xiang Zhang, Wen Wu, Wei Jiang, Wei Zhao, Hua Xie, Jing Zhang, Dong Li, Taisheng Xiao, Meng Wang, Jinglan Gao, Peng Ma, Jie Sun, Xuefeng Xia, Peng Cao, Wei Zhang, Hongmin Wu, Dong Zhang, Fengchun Xu, Yingchun Zhang, Shuyang Liu, Zhengyin Qin, Yan Yan, Xiaowei Ding, Xin Wu, Xian Hou, Xin Lu, Minya Qin, Xuzhen Wang, Chunyao Zhang, Shulan Zhao, Yongqiang
Source	Medline; PMC
abstract	OBJECTIVES: Coagulopathy is one of the characteristics of critically ill patients with Coronavirus Disease 2019 (COVID‐19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, but their role in COVID‐19 remains unclear. We aimed to determine the prevalence and characteristics of aPLs in patients with COVID‐19. METHODS: Sera collected from 66 critically ill and 13 non‐critically ill patients with COVID‐19 were tested for anti‐cardiolipin (aCL) and anti‐β2‐glycoprotein 1 (aβ2GP1) (IgG, IgM, and IgA) and IgG aβ2GP1‐D1 by the chemiluminescence assay (CIA) and IgM and IgG anti‐phosphatidylserine/prothrombin (aPS/PT) by ELISA. RESULTS: aPLs were detected in 47.0% of critically ill patients (31/66), but not in patients with non‐critical conditions. IgA aβ2GP1 was the most common aPL, present in 28.8% (19/66) critically ill patients, followed by IgA aCL (25.8%,17/66) and IgG aβ2GP1 (18.2%,12/66). For multiple aPLs, IgA aβ2GP1+IgA aCL was the most common type (22.7%, 15/66), followed by IgA aβ2GP1+IgA aCL+ IgG aβ2GP1 (15.2%, 10/66). aPLs emerge around 35‐39 days post‐disease onset. Dynamic analysis of aPLs revealed 4 patterns based on persistence or transient appearance of the aPLs. Patients with multiple aPLs displayed significantly higher incidence of cerebral infarction (p=0.023). CONCLUSIONS: aPLs were common in critically ill patients. Multiple medium or high levels aPLs may help identify patients at risk of developing cerebral infarction. aPLs may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID‐19 may trigger the development of “COVID‐19‐induced‐APS‐like‐syndrome”. Long‐term follow‐up on COVID‐19 patients positive for aPLs would be of great importance.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1002/art.41425
bibo:pmid	32602200
has license	no-cc
sha1sum (hex)	72403dbb187a5d072691c3c0ff6da4fc3c73ed24
schema:url	https://doi.org/10.1002/art.41425
resource representing a document's title	Brief Report: Anti‐phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID‐19)
has PubMed Central identifier	PMC7361932
has PubMed identifier	32602200
schema:publication	Arthritis Rheumatol
resource representing a document's body	covid:72403dbb187a5d072691c3c0ff6da4fc3c73ed24#body_text
is schema:about of	named entity 'coagulopathy' named entity 'ROLE' named entity 'aPLs' named entity 'COVID-19' named entity 'COVID-19' named entity 'cerebral infarction' named entity 'intestinal mucosa' named entity 'IgA' named entity 'SLE' named entity 'anticoagulants' named entity 'thrombi' named entity 'IgM' named entity 'isolation ward' named entity 'critically ill patients' named entity 'IgA' named entity 'immune tolerance' named entity 'proinflammatory' named entity 'cerebral infarction' named entity 'aPLs' named entity 'plasma' named entity 'International Society on Thrombosis and Haemostasis' named entity 'aPL' named entity 'aPLs' named entity 'cutoff values' named entity 'aPLs' named entity 'CIA' named entity 'IgA' named entity 'aPLs' named entity 'COVID-19' named entity 'aPLs' named entity 'IgG' named entity 'cutoff values' named entity 'hypercoagulable state' named entity 'COVID-19' named entity 'COVID-19' named entity 'aPLs' named entity 'Infection' named entity 'aPLs' named entity 'IgA' named entity 'COVID-19' named entity 'hypercoagulable state' named entity 'long-term' named entity 'IgG' named entity 'COVID-19' named entity 'IgG' named entity 'antiphospholipid antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software